Elutia, Inc. · NASDAQ:ELUT
Elutia — Q2 2026 Earnings Presentation
24 slides from Elutia's earnings presentation, Aug 13, 2026
Slide 1: Second Quarter 2026 Conference Call
Second Quarter 2026 Conference Call Financial Results and Business Update Nasdaq: ELUT C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer August 13, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,
Slide 3: Today's Agenda
TODAY’S AGENDA 1 2Q26 Business Highlights 2Q 2026 Earnings 2 Where We’re Headed and Why Call August 13, 2026 3 Strategic Divestiture and Funding Update C. Randal Mills, PhD Chief Executive Officer Matt Ferguson Chief Financial Officer 4 Operational and Business Update 5 Financial Update 6 Closing Re
Slide 4: Business Highlights
Business Highlights Capital Secured to Fund NXT41x Through Independent Blinded Survey Validates Clearance and Commercial Launch Surgeon Demand for NXT41x $26 million secured without an equity offering, funding 50 plastic and reconstructive surgeons surveyed blind. Elutia through NXT41x clearance and
Slide 5: What are we great at?
What are we great at? Optimal Biologic Matrix + Powerful Antibiotics Sustained antibiotic release to prevent bacterial colonization and associated complications. Sold to Boston Scientific for $88M 5
Slide 6: Breast Cancer Surgery Is a Transformational Opportunity
Breast Cancer Surgery Is a Transformational Opportunity A $1.5B U.S. market with no meaningful innovation in the standard of care Big Market Big Problem Proven Solution $1.5B 15-20% $88M U.S. breast cancer surgery TAM Post-op infection rate after Boston Scientific acquired our mastectomy first-gener
Slide 7: The Unmet Need Is Severe
The Unmet Need Is Severe Status quo is not addressing post-operative infection in plastic and reconstructive surgery 1 in 3 15-20% 21% $48,344 Suffer serious Experience post-operative Up to 21% result in implant Average hospital cost of post-reconstruction infection loss reconstruction infection com
Slide 8: Better Understanding the Stakeholder Impact
Better Understanding the Stakeholder Impact The consequences of surgical site infection are far-reaching The The The Patient Hospital Surgeon • Pain, fear, and multiple trips to • Unplanned cost, largely • Called back nights, weekends, the operating room absorbed without reimbursement holidays • Che
Slide 9: Strategic Divestiture and Funding Update
Strategic Divestiture and Funding Update 9
Slide 10: Capital Secured to Support NXT41x Through Clearance and Commercial Launch
Capital Secured to Support NXT41x Through Clearance and Commercial Launch Up to $26 million secured without an equity offering $15M $11M $26M Credit facility SimpliDerm divestiture of additional capital secured • $10 million funded at closing • $8 million in cash at closing • $5 million available up
Slide 11: Product Divestitures Sharpen Elutia's Focus
Product Divestitures Sharpen Elutia’s Focus All efforts are now focused on the launch of NXT41x NXT41x SimpliDerm SI GN ED Definitive agreement signed July 16, 2026 for up to $11 million. Closing expected in 3Q 2026. Capital, organization, and attention concentrated Cardiovascular entirely on NXT41x
Slide 12: Operational and Business Update
Operational and Business Update 12
Slide 13: Independent Blinded Survey Tests Surgeon Demand for NXT41x
Independent Blinded Survey Tests Surgeon Demand for NXT41x TH E P A NE L TH E M E THO D 50 board-certified plastic and reconstructive Independent and blinded surgeons Fielded by an outside research firm. Elutia was never named, and the product was described only as Product X. 11.6 yrs average time i
Slide 14: Surgeons say the problem of post-operative infection is real
Surgeons say the problem of post-operative infection is real What they believe the SSI rate actually is 86% CI 74-93% 17.0% say the matrices they use today increase the risk of surgical site infection This is not our claim about a competitor. It is the surgeons describing the current products as a r
Slide 15: Surgeons View NXT41x as Differentiated and Mechanistically Sound
Surgeons View NXT41x as Differentiated and Mechanistically Sound 96% 64% 98% CI 87-99% CI 50-76% CI 90-99.6% rate the combination extremely rate rifampin and minocycline rated NXT41x new and different effective (subset of the prior effective at reducing SSI from products available today question) Th
Slide 16: Surgeon Intent to Adopt NXT41x Is Strong
Surgeon Intent to Adopt NXT41x Is Strong 100% 96% 92% CI 93-100% CI 87-99% CI 81-97% indicated they would use NXT41x indicated willingness to approach expressed interest in incorporating in diabetic patients and in patients their hospital value analysis NXT41x into their general practice with high B
Slide 17: Demand for NXT41x Is No Longer a Hypothesis
Demand for NXT41x Is No Longer a Hypothesis We asked if the problem We asked if our approach We asked if they would We asked if they would was real would work use it fight for it 86% 96% 96% 92% say the matrices they use rate the antibiotic expressed interest in would approach their own today increa
Slide 18: NXT41 510(k) FDA Review Remains On-Track
NXT41 510(k) FDA Review Remains On-Track Collaborative dialogue with FDA increasing confidence in NXT41x submission NXT41 Submission NXT41 Expected Clearance SUBMITTED 4Q 2026 NXT41x Submission NXT41x Expected Clearance 4Q 2026 1H 2027 18
Slide 19: We Own the Process End-to-End
We Own the Process End-to-End Integrated in-house manufacturing drives control, margin, and defensibility Installation and operational qualification of the automated drug-coating system are complete! Built in-house, end-to-end. No contract manufacturer. No licensing. No single- source supplier depen
Slide 20: 2Q 2026 Financial Results
2Q 2026 Financial Results S) Medicine Humanized
Slide 21: 2Q26 Financial Summary
2Q26 Financial Summary REVENUE MARGIN & PROFITABILITY BALANCE SHEET & CASH • Total net sales: $2.4M vs. $2.7M in • GAAP gross margin: 59.6% vs. • Cash on hand (Jun 30): $19.9M 2Q25 52.9% • Up to $34M more from signed – SimpliDerm: down $0.7M on contract • Adj. gross margin (Non-GAAP): transactions m
Slide 22: Funded Through Clearance and the First Full Year of Launch
CA PITAL Funded Through Clearance and the First Full Year of Launch Funded catalysts ahead Expected Timing $20M + $34M SimpliDerm divestiture close 3Q 2026 Up to $54M available, without an equity offering Potential Cardiovascular transaction 2H 2026 • $15M credit facility $8M BioEnvelope escrow rele
Slide 23: Investment Summary
Investment Summary Validated Platform Blockbuster Pipeline Fully Resourced We can Reconstruction is We have Develop it. $1.5B market. Proven team. Clear it. 162,000 surgeries. Existing GMP facility. Commercialize it. 15-20% infection rate. Cash to fund the company through product approval and full c
Slide 24: Thank you!
Thank you! Its GO time! S) Medicine Humanized